A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients

NCT02253264 ·Status: COMPLETED ·Phase: PHASE1

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

NCT05834855 ·Status: RECRUITING ·Phase: PHASE3

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

NCT06735248 ·Status: RECRUITING ·Phase: PHASE2

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate

NCT01569451 ·Status: COMPLETED ·Phase: PHASE2

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT00882999 ·Status: COMPLETED ·Phase: PHASE2

A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS)

NCT06681623 ·Status: RECRUITING

Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis

NCT04480307 ·Status: COMPLETED ·Phase: PHASE2

Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases

NCT02040116 ·Status: COMPLETED ·Phase: PHASE4

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

NCT02738775 ·Status: COMPLETED ·Phase: PHASE2

Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients

NCT03315923 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

NCT01212094 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

NCT00035529 ·Status: TERMINATED ·Phase: PHASE2

An Extension of the TG1101-RMS201 Trial

NCT03381170 ·Status: COMPLETED ·Phase: PHASE2

Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT01457924 ·Status: COMPLETED ·Phase: PHASE2

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

NCT05758831 ·Status: RECRUITING ·Phase: PHASE3

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

NCT01405820 ·Status: COMPLETED ·Phase: PHASE2

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

NCT06617793 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

NCT00027300 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)

NCT03277248 ·Status: COMPLETED ·Phase: PHASE3

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

NCT04625153 ·Status: TERMINATED ·Phase: PHASE2

Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis

NCT01719159 ·Status: COMPLETED ·Phase: PHASE2

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

NCT02601885 ·Status: COMPLETED ·Phase: PHASE1

Intrathecal Rituximab in Progressive Multiple Sclerosis

NCT02545959 ·Status: COMPLETED ·Phase: PHASE2

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

NCT00640328 ·Status: COMPLETED ·Phase: PHASE2

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two

NCT00548405 ·Status: COMPLETED ·Phase: PHASE3